Latest news
6 September 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNA). Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability. Customers can gain access to Touchlight’s dbDNA as an integral part of Lonza’s offering, benefiting from end-to-end mRNA … Continued
22 August 2022
Touchlight awarded ILAP for therapeutic DNA vaccine
Touchlight has been officially awarded an Innovation Passport through Innovative Licensing and Access Pathway (ILAP) for its therapeutic DNA vaccine, a vaccine that targets head and neck squamous cell carcinoma (HNSCC). ILAP is a novel pathway formed by the MHRA, NICE, SMC, and the AWTTC, supporting innovative approaches to the safe, timely and efficient development … Continued
6 July 2022
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization Access to dbDNA patent rights enables Pfizer’s rapid production of … Continued
1 March 2022
Touchlight and Versameb announce GMP manufacturing supply agreement
Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Hampton, UK, Basel, Switzerland – 1 March 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing … Continued
8 February 2022
AskBio and Touchlight Restructure Joint Venture
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV. Under the revised arrangement implemented on 1 February 2022, both parties benefit from co-exclusive rights … Continued
22 November 2021
Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced that it ranked number 4 in the 2021 Deloitte UK Technology Fast 50, a ranking of the 50 fastest-growing technology companies in the UK. Rankings are based on percentage revenue growth over the last four years. Touchlight grew 11,421 … Continued
15 October 2021
Touchlight to break ground on world’s highest-capacity DNA manufacturing facility
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK. The project will include the repair and renovation of a key remaining part of the Morelands and Riverdale Buildings, a … Continued
11 October 2021
Touchlight expands commercial team amid rapid company growth
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has announced the appointment of three new hires to expand the capabilities of its growing commercial team. Robin Bodicoat joins as Head of Marketing, Rhona McIntyre as Head of Sales for Europe, and Julie Foster as Head of Sales for North … Continued
15 September 2021
Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces extension of its fundraising round to a current aggregate total of US $125 million (£92 million GBP). The round was led by Bridford Investments Limited and Novator Partners. Demand for Touchlight’s proprietary synthetic DNA vector, dbDNA™, has grown rapidly … Continued
28 July 2021
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats
Touchlight’s doggybone DNA™ to be used in Pandemic Prevention Platform (P3) programme funded by Defense Advanced Research Projects Agency (DARPA) • For the first time, novel synthetic DNA combined with state-of-the-art delivery will be used to deliver neutralising antibody therapies and enable faster pandemic response • Touchlight recently raised £42 million ($58 million) to expand … Continued
11 March 2021
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand Completed facility will have capacity to manufacture up to 1 kg GMP DNA per month, enough for more than 1 billion Covid-19 vaccine doses Company’s growth driven by exceptional demand in all areas of genetic medicine, including mRNA and viral vectors for Covid-19 … Continued
3 December 2020
Touchlight appoints Satish Muchakayala as Director of Regulatory Affairs
Touchlight announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. Hampton, UK – 03 December 2020 Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. In … Continued
Upcoming events
mRNA-based therapeutics summit
Join us at the mRNA-based therapeutics summit in Boston, US (July 26-28, 2023).
Our team will be available to discuss your advanced therapy manufacturing. Learn how our enzymatically produced DNA vector called doggybone DNA (dbDNA) can significantly improve speed to manufacture, safety and scalability in comparison to plasmid DNA, for vaccine development.